Pfizer announces deal with Canada for experimental COVID-19 vaccine
OTTAWA: Pharmaceutical giant Pfizer and German biotech firm BioNTech on Wednesday (Aug 5) said they had signed a deal to supply Canada with an experimental coronavirus vaccine.
Deliveries of the BNT162 mRNA-based vaccine candidate are planned over the course of 2021, subject to clinical success and Health Canada approval, the two companies said in a statement. They did not reveal financial details.
READ: Moderna in talks to supply countries with COVID-19 vaccine; US$32-$37 a dose for smaller deals
Separately, the Canadian government said it would make an announcement on the next steps in procuring vaccines later on Wednesday.
There are no approved vaccines for the illness caused by the coronavirus, but 19 vaccines are being tested in humans around the world.